Cannabinoid CB1 receptor antagonists as potential pharmacotherapies for drug abuse disorders

References

• Aceto MD, Scates SM, Lowe JA, Martin BR. Dependence on delta 9-tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. Journal of Pharmacology and Experimental Therapeutics 1996; 278: 1290–1295
   PubMed Web of Science ®Google Scholar
• Aceto MD, Scates SM, Martin BB. Spontaneous and precipitated withdrawal with a synthetic cannabinoid, WIN 55212-2. European Journal of Pharmacology 2001; 416: 75–81
   PubMed Web of Science ®Google Scholar
• Anggadiredja K, Nakamichi M, Hiranita T, Tanaka H, Shoyama Y, Watanabe S, et al. Endocannabinoid system modulates relapse to methamphetamine seeking: Possible mediation by the arachidonic acid cascade. Neuropsychopharmacology 2004; 29: 1470–1478
   PubMed Web of Science ®Google Scholar
• Anthenelli RM, Despres J-P. Effects of rimonabant in the reduction of major cardiovascular risk factors. Results from the STRATUS-US Trial (Smoking Cessation in Smokers Motivated to Quit) and the RIO-LIPIDS Trial (Weight Reducing and Metabolic Effects in Overweight/Obese Patients with Dyslipidemia). Paper delivered at the 53rd Annual American College of Cardiology Scientific Session. New Orleans 2004, March 2004
   Google Scholar
• Arnone M, Maruani J, Chaperon F, Thiebot MH, Poncelet M, Soubrie P, et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997; 132: 104–106
   PubMed Web of Science ®Google Scholar
• Balerio GN, Aso E, Berrendero F, Murtra P, Maldonado R. Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice. European Journal of Neuroscience 2004; 20: 2737–2748
   PubMed Web of Science ®Google Scholar
• Bass CE, Griffin G, Grier M, Mahadevan A, Razdan RK, Martin BR. SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study. Pharmacology, Biochemistry and Behavior 2002; 74: 31–40
   PubMedGoogle Scholar
• Beardsley PM, Thomas BF. Current evidence supporting a role of cannabinoid CB1 receptor (CB1R) antagonists as potential pharmacotherapies for drug abuse disorders. Behavioural Pharmacology 2005; 16: 275–296
   PubMed Web of Science ®Google Scholar
• Boctor SY, Martinez Jr JL, Koek W, France CP. The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding. European Journal of Pharmacology 2007; 571: 39–43
   PubMed Web of Science ®Google Scholar
• Braida D, Pozzi M, Parolaro D, Sala M. Intracerebral self-administration of the cannabinoid receptor agonist CP 55,940 in the rat: Interaction with the opioid system. European Journal of Pharmacology 2001; 413: 227–234
   PubMed Web of Science ®Google Scholar
• Cahill K, Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Systematic Reviews Issue 4. Art No.: CD005353, DOI: 10.1002/14651858.CD005353.pub 3
   Google Scholar
• Caille S, Parsons LH. SR141716A reduces the reinforcing properties of heroin but not heroin-induced increases in nucleus accumbens dopamine in rats. European Journal of Neuroscience 2003; 18: 3145–3149
   PubMedGoogle Scholar
• Castañé A, Valjent E, Ledent C, Parmentier M, Maldonado R, Valverde O. Lack of CB1 cannabinoid receptors modifies nicotine behavioural responses, but not nicotine abstinence. Neuropharmacology 2002; 43: 857–867
   PubMed Web of Science ®Google Scholar
• Chaperon F, Soubrie P, Puech AJ, Thiebot MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 1998; 135: 324–332
   PubMed Web of Science ®Google Scholar
• Chiang YC, Chen JC. The role of the cannabinoid type 1 receptor and down-stream cAMP/DARPP-32 signal in the nucleus accumbens of methamphetamine-sensitized rats. Journal of Neurochemistry 2007; 103: 2505–2517
   PubMedGoogle Scholar
• Cippitelli A, Bilbao A, Hansson AC, del Arco I, Sommer W, Heilig M, et al. Cannabinoid CB1 receptor antagonism reduces conditioned reinstatement of ethanol-seeking behavior in rats. European Journal of Neuroscience 2005; 21: 2243–2251
   PubMedGoogle Scholar
• Cohen C, Perrault G, Griebel G, Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: Reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 2005; 30: 145–155
   PubMed Web of Science ®Google Scholar
• Cohen C, Perrault G, Voltz C, Steinberg R, Soubrie P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behavioural Pharmacology 2002; 13: 451–463
   PubMed Web of Science ®Google Scholar
• Colombo G, Vacca G, Serra S, Carai MA, Gessa GL. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR 141716, on alcohol's motivational properties in alcohol-preferring rats. European Journal of Pharmacology 2004; 498: 119–123
   PubMedGoogle Scholar
• Corbille AG, Valjent E, Marsicano G, Ledent C, Lutz B, Herve D, et al. Role of cannabinoid type 1 receptors in locomotor activity and striatal signaling in response to psychostimulants. Journal of Neuroscience 2007; 27: 6937–6947
   PubMedGoogle Scholar
• Cossu G, Ledent C, Fattore L, Imperato A, Bohme GA, Parmentier M, et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behavioural Brain Research 2001; 118: 61–65
   PubMed Web of Science ®Google Scholar
• Cramois N, Podvin J-M. Two pivotal studies indicate Acomplia™ (Rimonabant) offers a novel approach to cardiovascular risk management in overweight/obese people and smokers. (Sanofi-synthelabo, press release), American College of Cardiology Annual Meeting. New Orleans 2004
   Google Scholar
• De Vries TJ, de Vries W, Janssen MC, Schoffelmeer AN. Suppression of conditioned nicotine and sucrose seeking by the cannabinoid-1 receptor antagonist SR141716A. Behavioural Brain Research 2005; 161: 164–168
   PubMed Web of Science ®Google Scholar
• De Vries TJ, Homberg JR, Binnekade R, Raaso H, Schoffelmeer AN. Cannabinoid modulation of the reinforcing and motivational properties of heroin and heroin-associated cues in rats. Psychopharmacology 2003; 168: 164–169
   PubMedGoogle Scholar
• De Vries TJ, Shaham Y, Homberg JR, Crombag H, Schuurman K, Dieben J, et al. A cannabinoid mechanism in relapse to cocaine seeking. Nature Medicine 2001; 7: 1151–1154
   PubMed Web of Science ®Google Scholar
• Diergaarde L, de Vries W, Raaso H, Schoffelmeer AN, De Vries TJ. Contextual renewal of nicotine seeking in rats and its suppression by the cannabinoid-1 receptor antagonist rimonabant (SR141716A). Neuropharmacology 2008; 55: 712–716
   PubMedGoogle Scholar
• Dyr W, Ligieza J, Kostowski W. The effect of cannabinoid CB(1) receptor antagonist rimonabant (SR-141716) on ethanol drinking in high-preferring rats. Alcohol 2008; 42: 509–512
   PubMedGoogle Scholar
• Economidou D, Mattioli L, Cifani C, Perfumi M, Massi M, Cuomo V, et al. Effect of the cannabinoid CB1 receptor antagonist SR-141716A on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology 2006; 183: 394–403
   PubMed Web of Science ®Google Scholar
• Fattore L, Martellotta MC, Cossu G, Mascia MS, Fratta W. CB1 cannabinoid receptor agonist WIN 55,212-2 decreases intravenous cocaine self-administration in rats. Behavioural Brain Research 1999; 104: 141–146
   PubMed Web of Science ®Google Scholar
• Fattore L, Spano MS, Cossu G, Deiana S, Fratta W. Cannabinoid mechanism in reinstatement of heroin-seeking after a long period of abstinence in rats. European Journal of Neuroscience 2003; 17: 1723–1726
   PubMed Web of Science ®Google Scholar
• Forget B, Barthelemy S, Saurini F, Hamon M, Thiebot MH. Differential involvement of the endocannabinoid system in short- and long-term expression of incentive learning supported by nicotine in rats. Psychopharmacology 2006; 189: 59–69
   PubMed Web of Science ®Google Scholar
• Forget B, Hamon M, Thiebot MH. Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats. Psychopharmacology 2005; 181: 722–734
   PubMed Web of Science ®Google Scholar
• Freedland CS, Poston JS, Porrino LJ. Effects of SR141716A, a central cannabinoid receptor antagonist, on food-maintained responding. Pharmacology, Biochemistry and Behavior 2000; 67: 265–270
   PubMed Web of Science ®Google Scholar
• Freedland CS, Sharpe AL, Samson HH, Porrino LJ. Effects of SR141716A on ethanol and sucrose self-administration. Alcoholism, Clinical and Experimental Research 2001; 25: 277–282
   PubMedGoogle Scholar
• Gallate JE, McGregor IS. The motivation for beer in rats: Effects of ritanserin, naloxone and SR 141716. Psychopharmacology 1999; 142: 302–308
   PubMed Web of Science ®Google Scholar
• Gerdeman GL, Schechter JB, French ED. Context-specific reversal of cocaine sensitization by the CB(1) cannabinoid receptor antagonist rimonabant. Neuropsychopharmacology 2008; 33: 2747–2759
   PubMedGoogle Scholar
• Gessa GL, Serra S, Vacca G, Carai MA, Colombo G. Suppressing effect of the cannabinoid CB1 receptor antagonist, SR147778, on alcohol intake and motivational properties of alcohol in alcohol-preferring sP rats. Alcohol and Alcoholism 2005; 40: 46–53
   PubMed Web of Science ®Google Scholar
• Ginsburg BC, Lamb RJ. Cannabinoid effects on behaviors maintained by ethanol or food: A within-subjects comparison. Behavioural Pharmacology 2006; 17: 249–257
   PubMedGoogle Scholar
• Hiranita T, Nawata Y, Sakimura K, Yamamoto T. Methamphetamine-seeking behavior is due to inhibition of nicotinic cholinergic transmission by activation of cannabinoid CB1 receptors. Neuropharmacology 2008; 55: 1300–1306
   PubMed Web of Science ®Google Scholar
• Kauer JA, Malenka RC. Synaptic plasticity and addiction. Nature Reviews Neuroscience 2007; 8: 844–858
   PubMed Web of Science ®Google Scholar
• Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-arachidonoyl glycerol. British Journal of Pharmacology 2002; 136: 550–557
   PubMed Web of Science ®Google Scholar
• Kobilo T, Hazvi S, Dudai Y. Role of cortical cannabinoid CB1 receptor in conditioned taste aversion memory. European Journal of Neuroscience 2007; 25: 3417–3421
   PubMedGoogle Scholar
• Kodas E, Cohen C, Louis C, Griebel G. Cortico-limbic circuitry for conditioned nicotine-seeking behavior in rats involves endocannabinoid signaling. Psychopharmacology 2007; 194: 161–171
   PubMed Web of Science ®Google Scholar
• Lallemand F, De Witte P. SR147778, a CB1 cannabinoid receptor antagonist, suppresses ethanol preference in chronically alcoholized Wistar rats. Alcohol 2006; 39: 125–134
   PubMed Web of Science ®Google Scholar
• Lallemand F, Soubrie P, De Witte P. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic alcohol administration combined with repeated re-exposures and withdrawals. Alcohol and Alcoholism 2004; 39: 486–492
   PubMedGoogle Scholar
• Lallemand F, Soubrie PH, De Witte PH. Effects of CB1 cannabinoid receptor blockade on ethanol preference after chronic ethanol administration. Alcoholism, Clinical and Experimental Research 2001; 25: 1317–1323
   PubMedGoogle Scholar
• Le Foll B, Goldberg SR. Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 2004; 15: 2139–2143
   PubMed Web of Science ®Google Scholar
• Lesscher HM, Hoogveld E, Burbach JP, van Ree JM, Gerrits MA. Endogenous cannabinoids are not involved in cocaine reinforcement and development of cocaine-induced behavioural sensitization. European Neuropsychopharmacology 2005; 15: 31–37
   PubMedGoogle Scholar
• Lichtman AH, Sheikh SM, Loh HH, Martin BR. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. Journal of Pharmacology and Experimental Therapeutics 2001; 298: 1007–1014
   PubMed Web of Science ®Google Scholar
• Lopez-Moreno JA, Gonzalez-Cuevas G, Navarro M. The CB1 cannabinoid receptor antagonist rimonabant chronically prevents the nicotine-induced relapse to alcohol. Neurobiology of Disease 2006; 25: 274–283
   PubMedGoogle Scholar
• Lupica CR, Riegel AC. Endocannabinoid release from midbrain dopamine neurons: A potential substrate for cannabinoid receptor antagonist treatment of addiction. Neuropharmacology 2005; 48: 1105–1116
   PubMed Web of Science ®Google Scholar
• Mas-Nieto M, Pommier B, Tzavara ET, Caneparo A, Da Nascimento S, Le Fur G, et al. Reduction of opioid dependence by the CB(1) antagonist SR141716A in mice: Evaluation of the interest in pharmacotherapy of opioid addiction. British Journal of Pharmacology 2001; 132: 1809–1816
   PubMed Web of Science ®Google Scholar
• Melis M, Pistis M, Perra S, Muntoni AL, Pillolla G, Gessa GL. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. Journal of Neuroscience 2004; 24: 53–62
   PubMed Web of Science ®Google Scholar
• Merritt LL, Martin BR, Walters C, Lichtman AH, Damaj MI. The endogenous cannabinoid system modulates nicotine reward and dependence. Journal of Pharmacology and Experimental Therapeutics 2008; 326: 483–492
   PubMed Web of Science ®Google Scholar
• Navarro M, Carrera MR, Del Arco I, Trigo JM, Koob GF, Rodriguez de Fonseca F. Cannabinoid receptor antagonist reduces heroin self-administration only in dependent rats. European Journal of Pharmacology 2004; 501: 235–237
   PubMed Web of Science ®Google Scholar
• Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. Journal of Neuroscience 2001; 21: 5344–5350
   PubMed Web of Science ®Google Scholar
• Nowak KL, Vinod KY, Hungund BL. Pharmacological manipulation of CB1 receptor function alters development of tolerance to alcohol. Alcohol and Alcoholism 2006; 41: 24–32
   PubMedGoogle Scholar
• Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Perio A, et al. SR147778 [5-(4-bromophenyl)-1-(2, 4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: Biochemical and pharmacological characterization. Journal of Pharmacology and Experimental Therapeutics 2004; 310: 905–914
   PubMed Web of Science ®Google Scholar
• Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. Federation of European Biochemical Societies Letters 1994; 350: 240–244
   PubMed Web of Science ®Google Scholar
• Rodriguez de Fonseca F, Roberts AJ, Bilbao A, Koob GF, Navarro M. Cannabinoid receptor antagonist SR141716A decreases operant ethanol self administration in rats exposed to ethanol-vapor chambers. Zhongguo Yao Li Xue Bao 1999; 20: 1109–1114
   PubMed Web of Science ®Google Scholar
• Rubino T, Vigano D, Zagato E, Sala M, Parolaro D. In vivo characterization of the specific cannabinoid receptor antagonist, SR141716A: Behavioral and cellular responses after acute and chronic treatments. Synapse 2000; 35: 8–14
   PubMed Web of Science ®Google Scholar
• Serra S, Brunetti G, Pani M, Vacca G, Carai MA, Gessa GL, et al. Blockade by the cannabinoid CB(1) receptor antagonist, SR 141716, of alcohol deprivation effect in alcohol-preferring rats. European Journal of Pharmacology 2002; 443: 95–97
   PubMed Web of Science ®Google Scholar
• Serra S, Carai MA, Brunetti G, Gomez R, Melis S, Vacca G, et al. The cannabinoid receptor antagonist SR 141716 prevents acquisition of drinking behavior in alcohol-preferring rats. European Journal of Pharmacology 2001; 430: 369–371
   PubMedGoogle Scholar
• Shoaib M. The cannabinoid antagonist AM251 attenuates nicotine self-administration and nicotine-seeking behaviour in rats. Neuropharmacology 2008; 54: 438–444
   PubMed Web of Science ®Google Scholar
• Singh ME, Verty AN, McGregor IS, Mallet PE. A cannabinoid receptor antagonist attenuates conditioned place preference but not behavioural sensitization to morphine. Brain Research 2004; 1026: 244–253
   PubMed Web of Science ®Google Scholar
• Solinas M, Justinova Z, Goldberg SR, Tanda G. Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats. Journal of Neurochemistry 2006; 98: 408–419
   PubMed Web of Science ®Google Scholar
• Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. Journal of Pharmacology and Experimental Therapeutics 2003; 306: 93–102
   PubMed Web of Science ®Google Scholar
• Solinas M, Scherma M, Tanda G, Wertheim CE, Fratta W, Goldberg SR. Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. Journal of Pharmacology and Experimental Therapeutics 2007; 321: 1127–1134
   PubMed Web of Science ®Google Scholar
• Soria-Gomez E, Matias I, Rueda-Orozco PE, Cisneros M, Petrosino S, Navarro L, et al. Pharmacological enhancement of the endocannabinoid system in the nucleus accumbens shell stimulates food intake and increases c-Fos expression in the hypothalamus. British Journal of Pharmacology 2007; 151: 1109–1116
   PubMed Web of Science ®Google Scholar
• Soyka M, Koller G, Schmidt P, Lesch OM, Leweke M, Fehr C, et al. Cannabinoid receptor 1 blocker rimonabant (SR 141716) for treatment of alcohol dependence: Results from a placebo-controlled, double-blind trial. Journal of Clinical Psychopharmacology 2008; 28: 317–324
   PubMed Web of Science ®Google Scholar
• Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nature & Neuroscience 2000; 3: 1073–1074
   PubMed Web of Science ®Google Scholar
• Vinklerová J, Nováková J, Šulcová A. Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. Journal of Psychopharmacology 2002; 16: 139–143
   PubMed Web of Science ®Google Scholar
• Vinod KY, Yalamanchili R, Thanos PK, Vadasz C, Cooper TB, Volkow ND, et al. Genetic and pharmacological manipulations of the CB(1) receptor alter ethanol preference and dependence in ethanol preferring and nonpreferring mice. Synapse 2008; 62: 574–581
   PubMedGoogle Scholar
• Xi ZX, Gilbert JG, Peng XQ, Pak AC, Li X, Gardner EL. Cannabinoid CB1 receptor antagonist AM251 inhibits cocaine-primed relapse in rats: Role of glutamate in the nucleus accumbens. Journal of Neuroscience 2006; 26: 8531–8536
   PubMed Web of Science ®Google Scholar
• Xi ZX, Spiller K, Pak AC, Gilbert J, Dillon C, Li X, et al. Cannabinoid CB1 receptor antagonists attenuate cocaine's rewarding effects: Experiments with self-administration and brain-stimulation reward in rats. Neuropsychopharmacology 2008; 33: 1735–1745
   PubMedGoogle Scholar
• Zaniewska M, McCreary AC, Przegalinski E, Filip M. Evaluation of the role of nicotinic acetylcholine receptor subtypes and cannabinoid system in the discriminative stimulus effects of nicotine in rats. European Journal of Pharmacology 2006; 540: 96–106
   PubMed Web of Science ®Google Scholar